GGrantIndex
Sort

48,018 grants matching immunotherapy

P5 - P-53-Based Vaccine for Small Cell Lung Cancer

$400,000
Dmitry Isaac Gabrilovich · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2012 · CA

Phenotypic, Functional and Transcriptional Heterogeneity in T Cell Exhaustion

$400,000
Weiguo Cui · Northwestern University At Chicago · R01 · FY2023 · AI

Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment

$400,000
Adam Shilling · Nanocan Therapeutics Corporation · R41 · FY2022 · CA

CANCER CENTER SUPPORT GRANT

$400,000
University Of Colorado Denver · P30 · FY2001 · CA

Regulation and function of nonlymphoid organ CD103 dendritic cells

$400,000
Stephanie S Watowich · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · AI

Evaluation of lead FANA oligos targeting FOXP3, with and without anti-PD-1 mAb, as an approach for cancer immunotherapy

$400,000
Veenu Aishwarya · Aum Lifetech, Inc. · R43 · FY2022 · CA

Activating TFEB to enhance the efficacy of immunotherapy for triple negative breast cancer

$400,000
Daping Fan · Promilead, Llc · R41 · FY2025 · CA

Point-of-care autologous CAR-T cell manufacturing

$400,000
Yu-Tsueng Liu · Aerocytek, Inc. · R43 · FY2025 · CA

Development of a DISE-inducing, short RNA therapeutic to treat ovarian cancer

$400,000
Robert Schickel · Nuago Therapeutics Inc · R42 · FY2025 · CA

SBIR Phase II: Clinical-Scale Suspension Bioreactor for Primary Hematopoietic Culture

$400,000
Todd A McAdams · Tissue Therapeutics · · FY2000 · TIP

Microsatellite Instability Sequencing via Single-Molecule DNA Re-Reading

$400,000
Anna Schibel · Electronic Biosciences, Inc. · R43 · FY2023 · CA

Calcium Dependent Signaling in Airway Epithelial Cells

$400,000
Alice S Prince · Columbia University Health Sciences · R01 · FY2015 · HL

A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer

$400,000
Jennifer June Sessions · Cynvec, Llc · R44 · FY2020 · CA

Allogeneic cell and gene therapy for neuroendocrine tumors

$400,000
Brian G Petrich · Expression Therapeutics · R43 · FY2025 · CA

A novel MICA/B based tumor-centric bispecific antibody that enhances NK cell activity in a hostile tumor microenvironment

$400,000
Hemanta Baruah · Aakha Biologics Inc. · R43 · FY2024 · CA

SIRPant Technology for anti-Cancer Immunity

$400,000
Nathanael McCurley · Sirpant Immunotherapeutics, Inc. · R42 · FY2021 · CA

Comprehensive Cancer Center Program at Fox Chase

$400,000
Jonathan D. Chernoff · Research Inst Of Fox Chase Can Ctr · P30 · FY2021 · CA

Enzymology of Mismatch Repair in Yeast

$400,000
Richard D Kolodner · Ludwig Institute For Cancer Res Ltd · R01 · FY2021 · GM

Protective and Pathologic Roles for CD8+ T cells in Leishmaniasis

$400,000
Phillip A. Scott · University Of Pennsylvania · R01 · FY2016 · AI

Phase 2 Study of Folfirinox Followed by Ipilimumab/GVAX in Pancreatic Cancer

$400,000
Dung T Le · Johns Hopkins University · R01 · FY2015 · FD

Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation

$400,000
Siu Kit Lam · Immunophotonics, Inc. · R44 · FY2021 · CA

OSTEOGENIC AND IMMUNOMODULATORY PROPERTIES OF DECIDUOUS TOOTH STEM CELLS

$400,000
Songtao Shi · University Of Pennsylvania · R01 · FY2015 · DE

Advancing Next Generation CAR-T cells for Renal Cell Carcinoma

$400,000
Premal Patel · Cellinfinity Bio, Inc. · R44 · FY2024 · CA

CAREER: Engineering Therapeutic Immune Responses with Artificial Antigen-Presenting Cells

$400,000
Tarek Fahmy · Yale University · · FY2008 · ENG

OSTEOGENIC AND IMMUNOMODULATORY PROPERTIES OF DECIDUOUS TOOTH STEM CELLS

$400,000
Songtao Shi · University Of Pennsylvania · R01 · FY2017 · DE